



Feidhmeannacht na Seirbhíse Sláinte
Health Service Executive

Feidhmeannacht na Seirbhíse Sláinte
Seirbhís Aisíocaíochta Cúraim Phríomhúil
Bealach amach 5 an M50
An Bóthar Thuaidh
Fionnghlas
Baile Átha Cliath 11
D11 XKF3

Health Service Executive
Primary Care Reimbursement Service
Exit 5, M50
North Road
Finglas
Dublin 11
D11 XKF3

Guthán: (01) 864 7100
Facs: (01) 834 3589

Tel: (01) 864 7100
Fax: (01) 834 3589

24th March 2017

Circular 011/17

Notice to remove Cialis and Levitra (PDE5 Inhibitors) from the Reimbursement List (Effective 1st April 2017)

Dear Doctor,

With effect from 1st April 2017 and in accordance with Section 18 – 19 and Section 21 of The Health (Pricing and Supply of Medical Goods) Act 2013 the HSE will remove from the list of reimbursable items the following PDE5 inhibitors (used to treat erectile dysfunction)

Cialis® / Tadalafil
Levitra® / Vardenafil

The HSE has decided to cease reimbursement of Phosphodiesterase type-5 (PDE5) inhibitors for the treatment of erectile dysfunction with the exception of low cost reference priced Sildenafil. Many European countries do not reimburse PDE5 inhibitors for this indication.

Formulations reimbursed under the High Tech arrangements for other indications (e.g. Pulmonary Arterial Hypertension) are not affected. Reimbursement support will no longer be provided under GMS and Community Drug Schemes from **1st April 2017**.

Continued reimbursement of higher cost PDE5 inhibitors for erectile dysfunction would reduce the capacity of the HSE to fund other services and technologies.

It is important to note that no exceptions will be made.

Yours faithfully,

Anne Marie Hoey
Primary Care Reimbursement & Eligibility